[go: up one dir, main page]

WO2006039327A3 - Methods of treatment or prophylaxis of amyloidogenic diseases of the eye or optic nerve - Google Patents

Methods of treatment or prophylaxis of amyloidogenic diseases of the eye or optic nerve Download PDF

Info

Publication number
WO2006039327A3
WO2006039327A3 PCT/US2005/034778 US2005034778W WO2006039327A3 WO 2006039327 A3 WO2006039327 A3 WO 2006039327A3 US 2005034778 W US2005034778 W US 2005034778W WO 2006039327 A3 WO2006039327 A3 WO 2006039327A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
prophylaxis
treatment
optic nerve
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/034778
Other languages
French (fr)
Other versions
WO2006039327A2 (en
Inventor
Myles J Jaffe
Charles S Tressler
Simon R Sinclair
Bernadette P Mckeon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of WO2006039327A2 publication Critical patent/WO2006039327A2/en
Publication of WO2006039327A3 publication Critical patent/WO2006039327A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides compositions and methods for the prophylactic or therapeutic treatment of amyloidogenic diseases of the eye including the optic nerve. Such methods comprise administering a therapeutic agent that reduces or eliminates optic amyloid deposits. The methods are especially useful for the therapeutic intervention and prophylaxis of Age-Related Maculopathy (ARM), Age-Related Macular Degeneration (ARMD), or Glaucomatous Optic Neuropathy (GON).
PCT/US2005/034778 2004-10-01 2005-09-27 Methods of treatment or prophylaxis of amyloidogenic diseases of the eye or optic nerve Ceased WO2006039327A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61529104P 2004-10-01 2004-10-01
US60/615,291 2004-10-01

Publications (2)

Publication Number Publication Date
WO2006039327A2 WO2006039327A2 (en) 2006-04-13
WO2006039327A3 true WO2006039327A3 (en) 2006-08-24

Family

ID=36143016

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/034778 Ceased WO2006039327A2 (en) 2004-10-01 2005-09-27 Methods of treatment or prophylaxis of amyloidogenic diseases of the eye or optic nerve

Country Status (1)

Country Link
WO (1) WO2006039327A2 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9146244B2 (en) 2007-06-12 2015-09-29 Ac Immune S.A. Polynucleotides encoding an anti-beta-amyloid monoclonal antibody
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
CN105169388A (en) * 2007-10-05 2015-12-23 基因技术公司 Humanized antibody
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1976877T5 (en) 2005-11-30 2017-09-29 Abbvie Inc Monoclonal antibodies against amyloid beta protein and uses thereof
CL2007002070A1 (en) 2006-07-14 2008-02-08 Ac Immune S A Genentech Inc CHEMERIC OR HUMANIZED ANTIBODY, OR FRAGMENTS OF THEM, WHICH SPECIFICALLY ADHER TO AT LEAST AN EPITHOPE IN THE BETA-AMYLOID PROTEIN; NUCLEIC ACID MOLECULA THAT CODIFIES IT; COMPOSITION THAT UNDERSTANDS IT; YOUR USE TO TREAT NURSING
US20100183513A1 (en) 2006-11-24 2010-07-22 Wolfgang Froestl N-(methyl) -1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer's
WO2008061796A2 (en) * 2006-11-24 2008-05-29 Ac Immune Sa Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
US20090022728A1 (en) * 2007-03-09 2009-01-22 Rinat Neuroscience Corporation Methods of treating ophthalmic diseases
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
GB0718737D0 (en) * 2007-09-25 2007-11-07 Glaxo Group Ltd Antibodies
AU2015200604B2 (en) * 2007-10-05 2016-10-27 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
US20100297012A1 (en) * 2007-10-05 2010-11-25 Andrea Pfeifer Humanized antibody
EP2311823A1 (en) 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
CA2783699C (en) 2009-12-08 2019-01-15 Case Western Reserve University Primary amine compounds for treating ocular disorders
MX358739B (en) 2010-08-14 2018-09-03 Abbvie Inc Star Amyloid-beta binding proteins.

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DENTCHEV ET AL.: "Amyloid-beta is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas", MOLECULAR VISION, September 2003 (2003-09-01), pages 184 - 190, XP003001744 *
JOHNSON ET AL.: "The Alzheimer's Abeta-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration", PNAS USA, vol. 99, no. 18, 2002, pages 11830 - 11835, XP003000979 *
KLINTWORTH: "The molecular genetics of the corneal dystrophies - current status", FRONTIERS IN BIOSCIENCE, vol. 8, 2003, pages 687 - 713, XP003000980 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US9146244B2 (en) 2007-06-12 2015-09-29 Ac Immune S.A. Polynucleotides encoding an anti-beta-amyloid monoclonal antibody
CN105169388A (en) * 2007-10-05 2015-12-23 基因技术公司 Humanized antibody
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies

Also Published As

Publication number Publication date
WO2006039327A2 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
WO2006039327A3 (en) Methods of treatment or prophylaxis of amyloidogenic diseases of the eye or optic nerve
WO2007044668A3 (en) Compstatin and analogs thereof for eye disorders
WO2007098122A3 (en) Methods for the treatment of macular degeneration and related eye conditions
WO2006042329A3 (en) Crig polypeptide for prevention and treatment of complement-associated disorders
WO2005046603A3 (en) Pyridine compounds
MX354184B (en) Alkoxy compounds for disease treatment.
WO2006055526A3 (en) Compositions useful to treat ocular neovascular diseases and macular degeneration
WO2008147883A8 (en) Prevention and treatment of complement-associated eye conditions
WO2010048332A3 (en) Compounds for treating ophthalmic diseases and disorders
WO2002058730A3 (en) Compositions for treatment of ocular neovascularization
WO2007076360A8 (en) (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
PH12015501207A1 (en) Amine derivative compounds for treating ophthalmic diseases and disorders
WO2008131368A3 (en) Styrenyl derivative compounds for treating ophthalmic diseases and disorders
MX2007008848A (en) Methods and compositions for the treatment of ocular disorders.
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
WO2006023544A3 (en) Therapeutic uses of inhibitors of rtp801
WO2009005794A3 (en) Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders
WO2007084684A3 (en) Therapeutic uses of inhibitors of rtp801
WO2010028088A3 (en) Sulfur-linked compounds for treating opthalmic diseases and disorders
WO2003006893A3 (en) Methods of inhibiting amyloid toxicity
WO2007133800A3 (en) Toll-like receptor (tlr) stimulation for ocular angiogenesis and macular degeneration
WO2007046083A3 (en) Compositions for treatment of eye diseases
WO2020190890A8 (en) Nicorandil derivatives
WO2008048675A3 (en) Treatment for age-related macular degeneration and other diseases of the eye
WO2007050793A3 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05802529

Country of ref document: EP

Kind code of ref document: A2